Shenzhen Weiguang Biological Products Co., Ltd.
卫光生物
002880
Shenzhen Stock Exchange
Company Profile
1.Excellent quality One of the first batch of enterprises passing GMP certification in China. Product quality is higher than the national standard, leading the domestic counterparts. 2. Advanced technologies Complete variety. High utilization rate. Technology export. 3.Strong innovation strength Developed the world's first SARS specific medicine. Developed the world's first human COVID-19 immunoglobulin for intravenous injection. Undertook more than 40 national, provincial and municipal science and technology projects. 4. Operation of plasmapheresis centers Plasmapheresis centers are among the highest in China in terms of the average volume of plasma collected. Pingguo Plasmapheresis Center ranks in the forefront of the industry in the volume of plasma collected. 5. Brand benefits Well-known brand in Guangdong. Products well sold in more than 30 provincial administration regions in china. 6. First -class platform Investment and financing platform. Life science park platform.
Full description
Shenzhen Weiguang Biological Products Co., Ltd. is a state-controlled listed enterprise in Guangming District mainly engaged in the R&D, production and sales of plasma-derived medicinal products (PDMPs). It adopts advanced international processes such as chromatography separation technology and nano membrane virus removal filtration technology. Its product yield is leading in China, and its quality standards are benchmarked against international standards. We have 11 varieties and 23 specifications of products approved for marketing, such as human albumin, human immunoglobulin (pH4) for intravenous injection, etc. We are a leading enterprise of PDMPs with high plasma utilization, complete product types， strong research and development strength，and significant brand effect in China. We are committed to becoming a pioneer of differentiated PDMPs’manufacturer in China and an innovator of global platform based biopharmaceuticals.